STRATA Skin Sciences Announces XTRAC Comeback Placements in the First Quarter of 2024
HORSHAM, Pa. April 30, 2024 - STRATA Skin Sciences, Inc. (STRATA or the Company) (NASDAQ: SSKN), a medical technology company specializing in dermatologic treatments, has recently announced the placement of six XTRAC devices with dermatology clinics in the first quarter of 2024. These placements are considered comebacks, as they involve clinics that were previously part of STRATA’s partner program but had terminated their relationship with the company in the past. Notable among these comebacks are Henry Ford Health System in Detroit, Integrated Dermatology Group, and several practices from the Schweiger Dermatology Group.
The XTRAC device developed by STRATA Skin Sciences is an innovative product used for the treatment of dermatologic conditions. It employs excimer technology, which delivers targeted UVB light therapy to affected areas of the skin, specifically targeting and treating plaque psoriasis, vitiligo, and atopic dermatitis. The device has gained significant recognition and positive outcomes in the field of dermatology.
The announcement of these comeback placements in the first quarter of 2024 comes as a hopeful sign for STRATA Skin Sciences. The company has faced challenges in recent times, as it recorded a cumulative net loss of $-11 million during the 12 months ending in the fourth quarter of 2023. This financial performance resulted in a negative return on investment (ROI) of -30.47%.The comeback placements indicate that STRATA Skin Sciences has managed to rebuild relationships and regain the trust of these dermatology clinics. Henry Ford Health System, Integrated Dermatology Group, and practices from the Schweiger Dermatology Group’s decision to return to STRATA under the partner program signify the credibility and effectiveness of the XTRAC device.
Dermatology clinics choosing to re-engage with STRATA Skin Sciences suggests that these medical professionals have recognized the value proposition and unique benefits offered by the XTRAC device. The device’s ability to provide effective and targeted treatments for various dermatologic conditions, coupled with STRATA’s commitment to developing and commercializing innovative products, seems to have influenced these comeback placements.
The comeback placements may serve as a turning point for STRATA Skin Sciences, giving the company an opportunity to rebuild its financial position and restore investor confidence. While the negative financial performance in the previous year may have raised concerns, the success of these recent placements demonstrates that STRATA’s products and collaborative partnerships remain attractive to leading dermatology clinics.
The future outlook for STRATA Skin Sciences appears promising with these comeback placements, as they not only bring in immediate revenue but also present opportunities for continued growth and expansion. With renewed partnerships and a focus on developing groundbreaking products, STRATA Skin Sciences is positioned to regain its position as a leading medical technology company in the field of dermatology.
Comments